Carregant...
A Severe Case of Cutaneous Adverse Drug Reaction Secondary to a Novice Drug: Idelalisib
Phosphatidylinositol 3-kinase δ (PIK3δ) is a tyrosine kinase essential for B cell survival, making it an important target in the treatment of chronic lymphocytic leukemia. Idelalisib is an inhibitor of PIK3δ demonstrating initial success in disease response, but is now shown to have a decreased over...
Guardat en:
| Publicat a: | J Investig Med High Impact Case Rep |
|---|---|
| Autors principals: | , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
SAGE Publications
2017
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5446100/ https://ncbi.nlm.nih.gov/pubmed/28589155 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2324709617711463 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|